<DOC>
	<DOCNO>NCT01552928</DOCNO>
	<brief_summary>According ICH Guidance Document E14 , non-antiarrhythmic drug evaluate ability prolong QT interval represent duration ventricular depolarization subsequent repolarization . The primary objective study assess effect anagrelide QT/QTc interval follow therapeutic supratherapeutic dose anagrelide compare placebo positive control .</brief_summary>
	<brief_title>Effect Anagrelide Hydrochloride Any Changes Heart Function Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Anagrelide</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Age 1845 year inclusive time consent . The date signing informed consent define begin screen period . This inclusion criterion assess screen visit . Subject willing comply applicable contraceptive requirement protocol : male , nonpregnant non lactate female , female must least 90 day postpartum nulliparous . Satisfactory medical assessment clinically relevant abnormality medical history , physical examination , vital sign , ECG , clinical laboratory evaluation assess investigator . Current recurrent disease could affect action , absorption , disposition investigational product , could affect clinical laboratory assessment . Current relevant history physical psychiatric illness , medical disorder may require treatment make subject unlikely fully complete study , condition present undue risk investigational product procedure . Significant illness , judge Investigator , within 2 week first dose investigational product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>